Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

BACKGROUND: The purpose of this study was to compare the efficacy of osimertinib (OSI) versus afatinib (AFA) in patients with T790M-positive, non-small-cell lung cancer (NSCLC) and multiple central nervous system (CNS) metastases after failure of initial epidermal growth factor receptor tyrosine kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yang, Liu, Qilong, Cao, Lei, Sun, Wei, Gu, Xiaowei, Liu, Bin, Xiao, Na, Teng, Fei, Li, Xiaoli, Chen, Meiji, Yu, Weiguang, Lin, Huanyi, Xu, Guixing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135149/
https://www.ncbi.nlm.nih.gov/pubmed/34011336
http://dx.doi.org/10.1186/s12890-021-01539-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135149/
https://www.ncbi.nlm.nih.gov/pubmed/34011336
http://dx.doi.org/10.1186/s12890-021-01539-x

Ejemplares similares